---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-027003"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:46:51.891085+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GeoVax Q3 net loss $3.97M; cash jumps to $34.7M; Phase 2 trials advance

## Summary
- Net loss $3.97M ($0.17/sh) for Q3 2022 vs $1.95M ($0.31) in Q3 2021; 9-month net loss $8.64M.
- Cash $34.7M at Sep 30, 2022 vs $11.4M at Dec 31, 2021; raised $27.7M from stock/warrant sales and $7.6M from warrant exercises.
- Phase 2 COVID vaccine GEO-CM04S1 advancing; Lancet Microbe data show robust neutralizing antibodies and T cells; expanding sites.
- Gedeptin Phase 1/2 for head and neck cancer expands to Emory and Thomas Jefferson; FDA orphan grant funded.
- Secured rights to NIH-MVA for monkeypox/smallpox; began preclinical studies for pan-coronavirus and MUC1 immunotherapy.

## SEC filing metadata
- accession: 0001437749-22-027003
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774922027003/0001437749-22-027003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774922027003/govx20221109_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-027003
- JSON: https://secwatch.observer/filing/0001437749-22-027003.json
- Plain text: https://secwatch.observer/filing/0001437749-22-027003.txt

## Key facts
- Earnings Releases
  GeoVax Labs, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 9, 2022, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/832489/000143774922027003/0001437749-22-027003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.